Developer docs
API playgroundTry for free, no card

Search company profiles

Spero Therapeutics

Full company profile

uuid0002lvs

Namestring
Spero Therapeutics
Legal namestring
Spero Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2013
Descriptiontext

Spero Therapeutics, Inc. is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company founded in 2013 and listed on NASDAQ (ticker SPRO) since November 2017, focused on developing therapeutics for multidrug-resistant (MDR) bacterial infections and rare infectious diseases. The company's lead asset, Utebzi (tebipenem pivoxil hydrobromide, formerly SPR994), is an oral carbapenem antibiotic that received FDA approval on June 17, 2026 for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis in adults, becoming the first and only oral carbapenem available in the U.S. The Phase 3 PIVOT-PO trial showed 58.5% clinical success versus 60.2% for IV imipenem-cilastatin. The pipeline additionally includes SPR206, an IV polymyxin derivative for MDR infections that is licensed to Pfizer for development outside the U.S. and Asian territories, and SPR720, an oral candidate for non-tuberculous mycobacterial pulmonary disease with Phase 1 data published.

Spero generates revenue primarily through licensing and collaboration economics rather than direct product sales. In September 2022, GSK acquired near-global rights to tebipenem HBr in exchange for a $66 million upfront payment, up to $750 million in potential milestones, tiered royalties on net sales, and a $9 million equity investment in Spero. Pfizer's 2021 deal for SPR206 provided $40 million in equity and licensing economics for ex-U.S./Asian territories. HealthCare Royalty Partners provided $125 million in revenue-interest financing in 2021, and BARDA's pediatric development contract has a potential value of up to $59.7 million in non-dilutive government funding. FY2025 revenue totaled $66.8 million, driven largely by collaboration milestone and grant recognition including a $25 million milestone from GSK triggered by NDA resubmission in December 2025.

The company operates through a small team of 11-50 employees and runs a partner-driven commercialization model: GSK leads global Utebzi commercialization via established hospital formularies, retail pharmacy networks, and specialty distributors, while Pfizer owns ex-U.S. development rights for SPR206. Headquartered at 675 Massachusetts Avenue in Cambridge, MA, Spero has been recognized multiple times as one of Boston's Best Places to Work by the Boston Business Journal (2020, 2021, 2024) and maintains $56.1 million in cash and equivalents as of Q1 2026 with an operating runway extending into 2028.

Short descriptiontext

Spero Therapeutics is a Cambridge, MA-based biopharmaceutical company developing oral carbapenem antibiotics and other therapeutics for multidrug-resistant bacterial infections, with its lead product Utebzi (tebipenem pivoxil) FDA-approved in June 2026 for complicated urinary tract infections.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibiotic drug development, multidrug-resistant infection therapies, oral carbapenem antibiotics, complicated urinary tract infection treatment, rare disease pharmaceuticals
Industry3 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Infectious Disease Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Licensing Royalties from GSK
TypeLicensing Royalties
Description

GSK pays Spero royalties on net sales of Utebzi (tebipenem pivoxil). Royalty structure rewards meaningful cash flow above $750M in annual net sales. Potential royalties of approximately $50 million annually with upside exceeding $100 million if blockbuster status achieved.

biospace.com
2Licensing Revenue from Pfizer
TypeLicensing Royalties
Description

Pfizer licensed SPR206 for development outside U.S. and Asian territories, with Spero receiving upfront payment and potential milestone payments.

pfizer.com
3BARDA Grant Funding
TypeProfessional Services
Description

Biomedical Advanced Research and Development Authority provides funding support for tebipenem pediatric development, totaling up to $59.7 million potential contract value.

globenewswire.com
4Revenue Interest Financing
TypeLicensing Royalties
Description

HealthCare Royalty Partners agreement providing upfront funding with potential milestones and royalties based on future revenue from medical products.

biospace.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Prescription pharmaceutical product for complicated urinary tract infections
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing not yet publicly disclosed as of FDA approval date June 2026. Market opportunity addresses over 3 million annual cUTI cases representing $6 billion in healthcare costs.

m.au.investing.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Spero Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of antibacterial and anti-infective medicines. Its lead commercial product is Utebzi (tebipenem pivoxil hydrobromide), the first and only oral carbapenem antibiotic approved in the U.S. for complicated urinary tract infections (cUTIs) including pyelonephritis in adults. The pipeline includes SPR206 (a polymyxin derivative for multi-drug resistant bacterial infections, licensed to Pfizer) and SPR720 (an oral agent for non-tuberculous mycobacterial pulmonary disease).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 58.5% overall success rate vs 60.2% for IV imipenem-cilastatin in PIVOT-PO Phase 3 trial
+3 more records
Product overview1 text field

Spero Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of investigational medicines targeting rare diseases and multidrug-resistant (MDR) bacterial infections. The company's lead product is Utebzi (tebipenem pivoxil hydrobromide), an FDA-approved oral carbapenem antibiotic for complicated urinary tract infections - the first and only oral carbapenem available in the US. The pipeline includes SPR206 (licensed to Pfizer for MDR bacterial infections) and SPR720 (in development for non-tuberculous mycobacterial pulmonary disease). The company operates through partnerships with major pharmaceutical companies including GSK (for tebipenem HBr) and Pfizer (for SPR206), with funding support from government agencies like BARDA.

Product and service3 records
1Utebzi (tebipenem pivoxil hydrobromide)
CategoryApproved Drug Product
Description

FDA-approved oral carbapenem antibiotic for treating complicated urinary tract infections (cUTIs) including pyelonephritis in adults. The first and only oral carbapenem approved in the U.S., developed to help patients avoid hospitalizations or transition home after IV therapy. Commercialized globally (outside Japan and certain Asian territories) by GSK under exclusive license.

2SPR206
CategoryLicensed Drug Candidate
Description

Investigational intravenous polymyxin derivative drug candidate for the treatment of multi-drug resistant bacterial infections. Licensed to Pfizer for development and commercialization outside of U.S. and Asian territories under a 2021 agreement that included a $40 million equity investment.

3SPR720
CategoryClinical Stage Asset
Description

Investigational oral drug candidate for the treatment of non-tuberculous mycobacterial (NTM) pulmonary disease. Phase 1 clinical trial results have been published. Remains in clinical-stage development.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-09-22
Description

Exclusive global licensing agreement for tebipenem HBr (Utebzi). GSK received rights to commercialize outside Japan and certain Asian territories. Spero received $66 million upfront, potential milestones up to $750 million, tiered royalties, and GSK purchased $9 million in Spero shares. FDA approved Utebzi on June 17, 2026 for cUTI in adults. GSK assumes NDA sponsorship and commercialization responsibilities.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-06-30
Description

$40 million equity investment and licensing agreement for SPR206, a drug candidate for multi-drug resistant bacterial infections. Pfizer purchased shares and obtained rights to develop and commercialize SPR206 outside U.S. and Asian territories. Spero uses funds to support clinical pipeline.

3Meiji Seika Pharma
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Strategic partner with logo displayed on Spero Therapeutics partnerships page; specific collaboration details not detailed in available sources.

sperotherapeutics.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Strategic partner with logo displayed on Spero Therapeutics partnerships page; specific collaboration details not detailed in available sources.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Melinta Therapeutics is a specialty antibiotics company commercializing drugs for serious bacterial infections, directly comparable as a focused anti-infective pharma with both marketed and development-stage carbapenem/quinolone assets.

TypeBroad incumbent
Description

GSK is Spero's primary commercialization partner (Utebzi global licensee) and a broad incumbent with extensive infectious disease and antibiotics heritage, comparable as the counterparty controlling Utebzi's commercial destiny.

TypeDirect peer
Description

Tetraphase developed eravacycline (Xerava), an IV antibiotic approved for complicated intra-abdominal infections, and was acquired by La Jolla Pharmaceutical — a relevant precedent for a small-cap anti-infective with a single approved asset.

TypeBroad incumbent
Description

Pfizer is both an Spero partner (SPR206 licensee, $40M equity investor) and a broad incumbent in the anti-infective space with established carbapenem franchises (meropenem) and large infectious disease R&D infrastructure that could compete in MDR infections.

TypeDirect peer
Description

Paratek Pharmaceuticals developed and commercialized omadacycline and tetracycline-class antibiotics, a comparable specialty anti-infective company that navigated similar FDA approval and partnership dynamics.

TypeDirect peer
Description

Iterum Therapeutics is developing oral antibiotics (sulopenem) for complicated urinary tract infections, directly competing with Spero's Utebzi in the same cUTI oral step-down market with similar patient population and prescriber base.

7Nabriva Therapeutics
TypeDirect peer
Description

Nabriva Therapeutics develops antibiotics for community-acquired pneumonia and complicated UTIs, making it a direct peer in the specialty anti-infective space with similar regulatory and commercialization challenges.

TypeDirect peer
Description

Cidara Therapeutics develops anti-infectives including antivirals and antibacterial conjugates, comparable to Spero as a small clinical-stage biopharma focused on novel anti-infective modalities.

TypeEmerging player
Description

BioMarin is a rare-disease focused biopharma with a similar small-cap commercial-stage model — relevant as a comp for how a specialty pharma of Spero's size monetizes a single high-need therapy through partnership-driven commercialization.

TypeDirect peer
Description

Innoviva acquired Entasis Therapeutics and VenatoRx, both of which developed novel antibiotics for multi-drug resistant bacterial infections — directly comparable to Spero's SPR206 program targeting the same MDR Gram-negative market.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds16 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Spero Therapeutics

Infectious Disease Pharmaceuticalssperotherapeutics.com

Spero Therapeutics is a Cambridge, MA-based biopharmaceutical company developing oral carbapenem antibiotics and other therapeutics for multidrug-resistant bacterial infections, with its lead product Utebzi (tebipenem pivoxil) FDA-approved in June 2026 for complicated urinary tract infections.

What Spero Therapeutics does

Spero Therapeutics, Inc. is a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company founded in 2013 and listed on NASDAQ (ticker SPRO) since November 2017, focused on developing therapeutics for multidrug-resistant (MDR) bacterial infections and rare infectious diseases. The company's lead asset, Utebzi (tebipenem pivoxil hydrobromide, formerly SPR994), is an oral carbapenem antibiotic that received FDA approval on June 17, 2026 for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritis in adults, becoming the first and only oral carbapenem available in the U.S. The Phase 3 PIVOT-PO trial showed 58.5% clinical success versus 60.2% for IV imipenem-cilastatin. The pipeline additionally includes SPR206, an IV polymyxin derivative for MDR infections that is licensed to Pfizer for development outside the U.S. and Asian territories, and SPR720, an oral candidate for non-tuberculous mycobacterial pulmonary disease with Phase 1 data published.

Spero generates revenue primarily through licensing and collaboration economics rather than direct product sales. In September 2022, GSK acquired near-global rights to tebipenem HBr in exchange for a $66 million upfront payment, up to $750 million in potential milestones, tiered royalties on net sales, and a $9 million equity investment in Spero. Pfizer's 2021 deal for SPR206 provided $40 million in equity and licensing economics for ex-U.S./Asian territories. HealthCare Royalty Partners provided $125 million in revenue-interest financing in 2021, and BARDA's pediatric development contract has a potential value of up to $59.7 million in non-dilutive government funding. FY2025 revenue totaled $66.8 million, driven largely by collaboration milestone and grant recognition including a $25 million milestone from GSK triggered by NDA resubmission in December 2025.

The company operates through a small team of 11-50 employees and runs a partner-driven commercialization model: GSK leads global Utebzi commercialization via established hospital formularies, retail pharmacy networks, and specialty distributors, while Pfizer owns ex-U.S. development rights for SPR206. Headquartered at 675 Massachusetts Avenue in Cambridge, MA, Spero has been recognized multiple times as one of Boston's Best Places to Work by the Boston Business Journal (2020, 2021, 2024) and maintains $56.1 million in cash and equivalents as of Q1 2026 with an operating runway extending into 2028.

Spero Therapeutics firmographics

Firmographics
Name
Spero Therapeutics
Legal name
Spero Therapeutics, Inc.
Website
https://sperotherapeutics.com
Company type
Public
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Spero Therapeutics is a Cambridge, MA-based biopharmaceutical company developing oral carbapenem antibiotics and other therapeutics for multidrug-resistant bacterial infections, with its lead product Utebzi (tebipenem pivoxil) FDA-approved in June 2026 for complicated urinary tract infections.
Ownership category
akta.pro rank

Spero Therapeutics industry classification

Industry
Product category
Infectious Disease Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAF
Pulmonology & Allergy Specialty Pharmaceuticals
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals

Keywords

  • Antibiotic drug development
  • Multidrug-resistant infection therapies
  • Oral carbapenem antibiotics
  • Complicated urinary tract infection treatment
  • Rare disease pharmaceuticals

Where Spero Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Spero Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing Royalties from GSK: GSK pays Spero royalties on net sales of Utebzi (tebipenem pivoxil). Royalty structure rewards meaningful cash flow above $750M in annual net sales. Potential royalties of approximately $50 million annually with upside exceeding $100 million if blockbuster status achieved.
  2. Licensing Revenue from Pfizer: Pfizer licensed SPR206 for development outside U.S. and Asian territories, with Spero receiving upfront payment and potential milestone payments.
  3. BARDA Grant Funding: Biomedical Advanced Research and Development Authority provides funding support for tebipenem pediatric development, totaling up to $59.7 million potential contract value.
  4. Revenue Interest Financing: HealthCare Royalty Partners agreement providing upfront funding with potential milestones and royalties based on future revenue from medical products.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPrescription pharmaceutical product for complicated urinary tract infections

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Spero Therapeutics product offering

Product offering

Core offering

Spero Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of antibacterial and anti-infective medicines. Its lead commercial product is Utebzi (tebipenem pivoxil hydrobromide), the first and only oral carbapenem antibiotic approved in the U.S. for complicated urinary tract infections (cUTIs) including pyelonephritis in adults. The pipeline includes SPR206 (a polymyxin derivative for multi-drug resistant bacterial infections, licensed to Pfizer) and SPR720 (an oral agent for non-tuberculous mycobacterial pulmonary disease).

Product overview

Spero Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of investigational medicines targeting rare diseases and multidrug-resistant (MDR) bacterial infections. The company's lead product is Utebzi (tebipenem pivoxil hydrobromide), an FDA-approved oral carbapenem antibiotic for complicated urinary tract infections - the first and only oral carbapenem available in the US. The pipeline includes SPR206 (licensed to Pfizer for MDR bacterial infections) and SPR720 (in development for non-tuberculous mycobacterial pulmonary disease). The company operates through partnerships with major pharmaceutical companies including GSK (for tebipenem HBr) and Pfizer (for SPR206), with funding support from government agencies like BARDA.

Differentiator

Problem solved

Functional benefit

Products and services

  • Utebzi (tebipenem pivoxil hydrobromide) FDA-approved oral carbapenem antibiotic for treating complicated urinary tract infections (cUTIs) including pyelonephritis in adults. The first and only oral carbapenem approved in the U.S., developed to help patients avoid hospitalizations or transition home after IV therapy. Commercialized globally (outside Japan and certain Asian territories) by GSK under exclusive license.
  • SPR206 Investigational intravenous polymyxin derivative drug candidate for the treatment of multi-drug resistant bacterial infections. Licensed to Pfizer for development and commercialization outside of U.S. and Asian territories under a 2021 agreement that included a $40 million equity investment.
  • SPR720 Investigational oral drug candidate for the treatment of non-tuberculous mycobacterial (NTM) pulmonary disease. Phase 1 clinical trial results have been published. Remains in clinical-stage development.

Quantifiable outcome

  • 58.5% overall success rate vs 60.2% for IV imipenem-cilastatin in PIVOT-PO Phase 3 trial
  • +3 more outcomes

Companies that use Spero Therapeutics

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Spero Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Spero Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship, core and minor.

  • GSK (GlaxoSmithKline)flagshipOEM/ Whitelabel/ Licensing Partner · 22 September 2022Exclusive global licensing agreement for tebipenem HBr (Utebzi). GSK received rights to commercialize outside Japan and certain Asian territories. Spero received $66 million upfront, potential milestones up to $750 million, tiered royalties, and GSK purchased $9 million in Spero shares. FDA approved Utebzi on June 17, 2026 for cUTI in adults. GSK assumes NDA sponsorship and commercialization responsibilities.
  • Pfizer Inc.coreOEM/ Whitelabel/ Licensing Partner · 30 June 2021$40 million equity investment and licensing agreement for SPR206, a drug candidate for multi-drug resistant bacterial infections. Pfizer purchased shares and obtained rights to develop and commercialize SPR206 outside U.S. and Asian territories. Spero uses funds to support clinical pipeline.
  • Meiji Seika PharmaminorStrategic or Co-development PartnerStrategic partner with logo displayed on Spero Therapeutics partnerships page; specific collaboration details not detailed in available sources.
  • Vertex PharmaceuticalsminorStrategic or Co-development PartnerStrategic partner with logo displayed on Spero Therapeutics partnerships page; specific collaboration details not detailed in available sources.

Scale indicators11 records

Recent moves7 records

Expansion highlights5 records

Spero Therapeutics competitors and assessment

Company assessment

Direct peers

  • Melinta Therapeutics: Melinta Therapeutics is a specialty antibiotics company commercializing drugs for serious bacterial infections, directly comparable as a focused anti-infective pharma with both marketed and development-stage carbapenem/quinolone assets.
  • Tetraphase Biosciences: Tetraphase developed eravacycline (Xerava), an IV antibiotic approved for complicated intra-abdominal infections, and was acquired by La Jolla Pharmaceutical — a relevant precedent for a small-cap anti-infective with a single approved asset.
  • Paratek Pharmaceuticals: Paratek Pharmaceuticals developed and commercialized omadacycline and tetracycline-class antibiotics, a comparable specialty anti-infective company that navigated similar FDA approval and partnership dynamics.
  • Iterum Therapeutics: Iterum Therapeutics is developing oral antibiotics (sulopenem) for complicated urinary tract infections, directly competing with Spero's Utebzi in the same cUTI oral step-down market with similar patient population and prescriber base.
  • Nabriva Therapeutics: Nabriva Therapeutics develops antibiotics for community-acquired pneumonia and complicated UTIs, making it a direct peer in the specialty anti-infective space with similar regulatory and commercialization challenges.
  • Cidara Therapeutics: Cidara Therapeutics develops anti-infectives including antivirals and antibacterial conjugates, comparable to Spero as a small clinical-stage biopharma focused on novel anti-infective modalities.
  • Innoviva Specialty Therapeutics (formerly Entasis/VenatoRx): Innoviva acquired Entasis Therapeutics and VenatoRx, both of which developed novel antibiotics for multi-drug resistant bacterial infections — directly comparable to Spero's SPR206 program targeting the same MDR Gram-negative market.

Broad incumbents

  • GSK (GlaxoSmithKline): GSK is Spero's primary commercialization partner (Utebzi global licensee) and a broad incumbent with extensive infectious disease and antibiotics heritage, comparable as the counterparty controlling Utebzi's commercial destiny.
  • Pfizer Inc. Pfizer is both an Spero partner (SPR206 licensee, $40M equity investor) and a broad incumbent in the anti-infective space with established carbapenem franchises (meropenem) and large infectious disease R&D infrastructure that could compete in MDR infections.

Emerging players

  • BioMarin Pharmaceutical: BioMarin is a rare-disease focused biopharma with a similar small-cap commercial-stage model — relevant as a comp for how a specialty pharma of Spero's size monetizes a single high-need therapy through partnership-driven commercialization.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Spero Therapeutics social profiles

Digital presence

Spero Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Spero Therapeutics leadership team

Management profile

Number of profiles

Profiles11 records

Spero Therapeutics funding detail

Funding detail

Funding overview

Funding rounds16 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Spero Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spero Therapeutics

What does Spero Therapeutics do?

Spero Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of antibacterial and anti-infective medicines. Its lead commercial product is Utebzi (tebipenem pivoxil hydrobromide), the first and only oral carbapenem antibiotic approved in the U.S. for complicated urinary tract infections (cUTIs) including pyelonephritis in adults. The pipeline includes SPR206 (a polymyxin derivative for multi-drug resistant bacterial infections, licensed to Pfizer) and SPR720 (an oral agent for non-tuberculous mycobacterial pulmonary disease).

Is Spero Therapeutics a public or private company?

Spero Therapeutics is a public company. It is classified as public and is currently operating.

When was Spero Therapeutics founded?

Spero Therapeutics was founded in 2013. It employs 11 to 50 people.

Where is Spero Therapeutics based?

Spero Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Spero Therapeutics make money?

Four revenue lines are on record. Licensing Royalties from GSK is the primary driver. The others are licensing Revenue from Pfizer, BARDA Grant Funding and revenue Interest Financing.

Who are Spero Therapeutics's main competitors?

Direct peers on record are Melinta Therapeutics, Tetraphase Biosciences, Paratek Pharmaceuticals, Iterum Therapeutics, Nabriva Therapeutics, Cidara Therapeutics and Innoviva Specialty Therapeutics (formerly Entasis/VenatoRx). Broad incumbents are GSK (GlaxoSmithKline) and Pfizer Inc.. BioMarin Pharmaceutical is listed as an emerging player.

Does Spero Therapeutics have an API?

No public API is recorded for Spero Therapeutics.

What industry is Spero Therapeutics in?

Spero Therapeutics's product category is Infectious Disease Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeSpero Reports $44.3 Million Third-Quarter Net Loss | SPRO Stock NewsSpero Therapeutics reported a $44.3 million net loss for Q3 2026, with no revenue. The company held $107.9 million in cash, expected to fund operations into H2 2029, and plans a Phase 2 study of SP001 in IgG4-related disease in Q2 2027.The future of tradingSpero Therapeutics Files Initial Beneficial Ownership Statement for Director William HoSpero Therapeutics director William Ho filed an initial beneficial ownership statement on Nov. 10, 2026. The filing was published via EDGAR, and the statement is for informational purposes only.Investing.comSpero Therapeutics at guggenheim conference: SP001 drives next phaseSpero Therapeutics outlined its next growth step at the Guggenheim conference, focusing on SP001, a third-generation anti-CD40 ligand antibody. The company plans a Phase II trial in IgG4-related disease in Q2 2027, backed by $105 million in non-dilutive funding and $50 million in cash. It aims to address thromboembolic safety concerns of earlier CD40 ligand drugs.The future of tradingSpero Therapeutics, Inc. <spro.oq> expected to post a loss of 47 cents a share - Earnings PreviewSpero Therapeutics is expected to report a quarterly loss of 47 cents per share on November 11, with revenue falling. Analysts rate the stock a buy, with a median price target of $6.00, about 482.5% above the last closing price of $1.03.American Banking and Market NewsSpero Therapeutics (SPRO) Expected to Announce Earnings on ThursdaySpero Therapeutics is expected to report Q3 2026 earnings after market close on November 12th, with analysts projecting a loss of $0.47 per share. The company's stock opened at $1.07, and analysts have an average rating of 'Hold' with a target price of $6.00.Stock TitanSpero Therapeutics to Join Two November ConferencesSpero Therapeutics will present at the Guggenheim Healthcare Innovation Conference on November 10 in Boston and the Jefferies Global Healthcare Conference on November 18-19 in London. CEO Esther Rajavelu will participate in a fireside chat, and the leadership team will be available for one-on-one meetings with investors.Business & FinancialSpero Therapeutics To Present At Investor Conferences In NovemberSpero Therapeutics will present at the Guggenheim Healthcare Innovation Conference on November 10 in Boston and the Jefferies Global Healthcare Conference on November 18-19 in London. The company's lead program, SP001, is a third-generation anti-CD40L antibody for IgG4-related disease.MarketBeatSpero Therapeutics (NASDAQ:SPRO) Stock Gets Downgrade from Wall Street ZenWall Street Zen downgraded Spero Therapeutics from hold to sell, while other analysts issued mixed ratings. The stock opened at $1.06, with a consensus hold and $6.00 target. Spero reported Q2 EPS of -$0.16, beating estimates.American Banking and Market NewsSpero Therapeutics (NASDAQ:SPRO) Rating Lowered to “Sell” at Wall Street ZenWall Street Zen downgraded Spero Therapeutics to a 'sell' rating, while other firms gave mixed ratings. The stock opened at $1.06, and the company reported a quarterly loss of $0.16 per share, beating estimates. Analysts expect a loss of $0.97 per share for the current year.American Banking and Market NewsSpero Therapeutics (NASDAQ:SPRO) Stock Picked Up by Analysts at Cantor FitzgeraldCantor Fitzgerald assumed coverage on Spero Therapeutics with an overweight rating and a $6.00 price target, implying 440.54% upside from the previous close. The stock opened at $1.11, and the company reported a loss of $0.16 per share for the quarter, beating estimates. Analysts have a consensus 'Hold' rating with a $6.00 price target.